BridgeMD
New treatment option for Hepatitis B
Official title The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
ClinicalTrials.gov ID: NCT04970836
What this study is testing
What is recombinant hepatitis B vaccine?
recombinant hepatitis B vaccine is an investigational medicine, being studied as a potential treatment for hepatitis b.
Also referred to as Engerix-B.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs titer\<10 mIU/mL) need to take.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 36. Healthy volunteers may be eligible.
You may be able to join if
- The actual age at the time of admission was higher than 20 years old and birth year after 1987
- Born in Taiwan and had received a full course of hepatitis B vaccines at least three doses at infant period.
- Those who have tested negative for hepatitis B surface antibody and surface antigen at baseline
- Have never been vaccinated against hepatitis B in childhood and adolescence by questionnaire
- Consent to administer 1-2 doses of hepatitis B vaccine according to the assigned group after sharing decision making process
You likely can't join if
- Those who were previously allergic to hepatitis B vaccine or its components (such as yeast)
- Those who have been vaccinated against hepatitis B during childhood and adolescence
- Those who have a positive test for hepatitis B surface antibody or a positive test for hepatitis B surface antigen
See the full eligibility criteria
- The actual age at the time of admission was higher than 20 years old and birth year after 1987
- Born in Taiwan and had received a full course of hepatitis B vaccines at least three doses at infant period.
- Those who have tested negative for hepatitis B surface antibody and surface antigen at baseline
- Have never been vaccinated against hepatitis B in childhood and adolescence by questionnaire
- Consent to administer 1-2 doses of hepatitis B vaccine according to the assigned group after sharing decision making process
- In good health
- Those who were previously allergic to hepatitis B vaccine or its components (such as yeast)
- Those who have been vaccinated against hepatitis B during childhood and adolescence
- Those who have a positive test for hepatitis B surface antibody or a positive test for hepatitis B surface antigen
The study team makes the final eligibility decision.
Where it's taking place
- Taipei, Taiwan
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 36 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taipei, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.